ReviewActa pharmaceutica Sinica. B2021
Influencing factors and strategies of enhancing nanoparticles into tumors
Review in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed.
- CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics.Nature reviews. Clinical oncology · 2026Review
- Biogenic Silver Nanoparticles from the Cell-Free Supernatant of Mychonastes sp. B1: Antibacterial and Antibiofilm Effects, and Wound Healing Activity Supported by Gene and Protein Expression Analysis.Molecular biotechnology · 2026Article
- Article
- Advances in Nanoarchitectural Designs for Anticancer Drug Delivery to Deep Tumors.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Intra-arterial delivery of FePt nanoparticles induces ferroptosis and immune infiltration to enhance radiotherapy.Materials today. Bio · 2026Article
- Advances in Polyethyleneimine-Derived Nanoformulations.Small science · 2026Review
- PEGylated Chitosan Nanoparticles: Engineering Multifunctional Platforms for Targeted Cervical and Lung Cancer Treatment.Cancer science · 2026Review
- Ligand-modified liposomes as drug delivery systems for the active targeting of pancreatic cancer.International journal of pharmaceutics: X · 2026Review
- Polysaccharide-functionalized gold, silver, and iron oxide nanoparticles for siRNA delivery: The role of artificial intelligence in design and optimization.Materials today. Bio · 2026Review
- Tuning mechanical softness as a design principle in drug delivery: A biomechanical perspective.Acta pharmaceutica Sinica. B · 2026Review
- Emerging mechanisms of microplastic-induced skin diseases: a perspective from the gut-skin axis.Journal of translational medicine · 2026Review
- AI-driven nanomedicine for cancer theranostics.Molecular cancer · 2026Review
- Whole-body distribution of threeAntimicrobial agents and chemotherapy · 2026Article
- Evaluation of the antiviral effect of casein nanoparticles (CNP) loaded with Plantago major extract (PME-CNP) on herpes simplex virus.Virology journal · 2026Article
- Development ofDrug delivery and translational research · 2026Article
- Ultrasound-Activated Nanoplatform Counteracts Triple-Negative Breast Cancer via Remodeling Intratumoral Microbiota-Metabolism and Inducing Ferroptosis.Biomaterials research · 2026Article
- Inhalable nanoparticle-based drug delivery system for non-small cell lung cancer therapy: promises and challenges.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025Review
- External stimuli-responsive drug delivery to the posterior segment of the eye.Drug delivery · 2025Review
- pH-Responsive Liposomes for Targeted Detection of Pancreatic Adenocarcinoma Using MSOT.Chemical & biomedical imaging · 2025Article
- Nanotechnology Driven Innovations in Modern Pharmaceutics: Therapeutics, Imaging, and Regeneration.Nanomaterials (Basel, Switzerland) · 2025Review
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The administration of nanoparticles (NPs) first faces the challenges of evading renal filtration and clearance of reticuloendothelial system (RES). After that, NPs infiltrate through the expanded endothelial space and penetrated the dense stroma of tumor microenvironment to tumor cells. As long as possible to prolong the time of NPs remaining in tumor tissue, NPs release active agent and induce pharmacological action. This review provides a comprehensive summary of the physical and chemical properties of NPs and the influence of various biological factors in tumor microenvironment, and discusses how to improve the final efficacy through adjusting the characteristics and structure of NPs. Perspectives and future directions are also provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.